\
&
Contact us
\
&
Contact us
info@ncpflanders.be
+32 2 550 15 65
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Research Infrastructures Health Culture and society Security
In the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA): Simplified section 2.1 'Project's pathways towards impac... read more
MSCA Research Infrastructures Health Culture and society
On 11 December 2025, the European Commission has adopted the Horizon Europe Main Work Programme 2026-2027 and has published it on the EU Funding & Tenders Portal. The Work Programmes can be found under reference documents on the Funding & Tenders Portal.On the NCP Flanders website the published work programmes can be consulte... read more
Partnerships unite the EC and private and/or public partners to work together in a specific domain. They offer often a good ecosystem to find collaborations.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
